Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Tianjin TEDA Biomedical Engineering Co Cash Conversion Cycle Related Terms
Tianjin TEDA Biomedical Engineering Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co Cash Conversion Cycle Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
FRA:TJJ vs CTVA, CF, MOS: Cash Conversion Cycle Comparison
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co Cash Conversion Cycle vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Cash Conversion Cycle falls into.
Tianjin TEDA Biomedical Engineering Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) has a Cash Conversion Cycle of 45.27 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors.
Is Tianjin TEDA Biomedical Engineering Co's Cash Conversion Cycle too high?
Tianjin TEDA Biomedical Engineering Co's current Cash Conversion Cycle is 45.27. The Agriculture industry median Cash Conversion Cycle is 102.53. Tianjin TEDA Biomedical Engineering Co's value of 45.27 is 55.8% below this industry median. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's Cash Conversion Cycle compare to CTVA and CF?
Tianjin TEDA Biomedical Engineering Co's Cash Conversion Cycle of 45.27 can be compared against companies in the Agriculture industry. The industry median Cash Conversion Cycle is 102.53. Tianjin TEDA Biomedical Engineering Co's value of 45.27 is 55.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for an Agriculture company?
The median Cash Conversion Cycle among Agriculture companies is 102.53, based on 249 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin TEDA Biomedical Engineering Co's current Cash Conversion Cycle of 45.27 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. For the Agriculture industry, the median Cash Conversion Cycle is 102.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current Cash Conversion Cycle is 45.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 115% above its estimated fair value. The current Cash Conversion Cycle is 45.27 and 55.8% below the Agriculture industry median of 102.53. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (FRA:TJJ), the current Cash Conversion Cycle is 45.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of €0.02 is trading 115% above its estimated GF Value™ of €0.01.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for FRA:TJJ:
Cash Conversion Cycle: 45.27
GF Value™: €0.01 vs. price of €0.02 (115% above fair value)
Industry Position: 55.8% below the Agriculture median
No single metric tells the full story. See the FRA:TJJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for FRA:TJJ
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TJJ has been successfully added to your 
